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(Wang et al., 2002), where neuronal
SIRT1 activation plays important roles
in the regulation of neuron survival in
ischemia and other neurodegenerative
conditions (Michan and Sinclair, 2007).
The current work by Sun et al. (2007),
together with previous studies, raises
the possibility that resveratrol’s effect
on body weight and insulin sensitivity
may be partly due to SIRT1 silencing
of neuronal PTP1B expression. Further
research is needed to delineate the
effects of resveratrol and SIRT1 on
insulin signaling in peripheral tissues
and hypothalamus to understand how
these important molecules regulate
insulin sensitivity and/or body weight
in vivo.
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Fatty acid synthase (FAS) is a key enzyme for lipogenesis. A recent study (Chakravarthy et al., 2007)
shows that the targeted deletion of FAS in hypothalamic neurons produces hypophagic, lean mice
and suggests that PPARa signaling is an important mediator of the effects of FAS on energy
homeostasis.Obesity rates are on the rise through-
out the world. The most serious public
health consequence of obesity is the
increasing rate of type 2 diabetes
mellitus. Weight loss dramatically
improves type 2 diabetes mellitus, but
we are still far from having efficient
and safe tools at hand to achieve
weight loss in patients. Up to now,
many genes have been identified that
make mice susceptible to diet-induced
obesity, yet the number of molecular
targets whose pharmacological inhibi-
tion induces marked weight loss in
obesity without undesirable side ef-
fects is very low. A recent paper (Chak-
ravarthy et al., 2007) demonstrates that
FAS in hypothalamic neurons repre-sents a promising molecular target
that may result in a novel approach
for treating obesity.
Consider the hypothalamus to be
the command center that governs not
only appetite but also glucose and
lipid metabolism in peripheral organs
like liver, adipose tissue, and muscle.
How are cues from the periphery
sensed by the hypothalamus to assess
the energy state of the organism, and
how are these integrated to control
energy homeostasis? In recent years,
it has become clear that the hypothal-
amus assimilates neuronal, hormonal,
and nutrient signals. The hypothala-
mus then integrates these signals to
regulate food intake and energyCell Metabolismmetabolism, presumably via the auto-
nomic nervous system. The serendipi-
tous discovery that the FAS inhibitor
C75, originally developed as an anti-
neoplastic agent, markedly reduces
body weight in mice pointed to FAS
as a potential integrator of hormonal
and nutrient signals within the hypo-
thalamus (Loftus et al., 2000). From
the outset, there were good indica-
tions that the anorectic effects of C75
were centrally mediated, as intracere-
broventricular administration of C75
replicated the anorectic effects of
systemic administration of C75. These
findings triggered a reconsideration
of the role of fatty acid metabolism in
energy homeostasis and advanced6, October 2007 ª2007 Elsevier Inc. 249
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PreviewsFigure 1. Fatty Acid Metabolism in Hypothalamic Neurons and the Regulation of
Food Intake
Citrate derived from the TCA cycle is released from mitochondria, provides cytoplasmic acetyl-
CoA, and allosterically activates the enzyme ACC. Acetyl-CoA is converted to malonyl-CoA by
ACC. Malonyl-CoA has two important functions: (1) it serves as a substrate for FAS, and (2) it in-
hibits CPT1, thereby limiting b-oxidation of fatty acids. Inhibition of ACC by AMP kinase (AMPK) as
well as pharmacological ACC inhibitors reduces malonyl-CoA and has been shown to increase
food intake. On the contrary, the overexpression of malonyl-CoA decarboxylase (MCD) in the hy-
pothalamus lowers malonyl-CoA and causes hyperphagia. Chakravarthy et al. (2007) show that
deletion of FAS leads to an accumulation of malonyl-CoA and suppression of PPARa target genes
like MCD and CPT1, resulting in suppressed food intake. Pharmacological PPARa activation in-
creases the mRNA expression of MCD and CPT1 and reverses the hypophagic phenotype of
mice with hypothalamic FAS deletion.the idea that the hypothalamus might
use malonyl-CoA (the substrate of
FAS; see Figure 1) as a key indicator
of whole-body energy availability.
Malonyl-CoA could modulate neuronal
activity by regulating intracellular sub-
strate fluxes to inhibit further food
intake (Ruderman et al., 2003; Loftus
et al., 2000). This paradigm, in which a
well-established cellular principle, the
regulation of substrate fluxes by
malonyl-CoA, might be the basis for a
nutrient-sensing mechanism that the
brain could use to orchestrate whole-
body energy homeostasis, electrified
the field. Yet some studies with C75
following the original report ques-
tioned the specificity of this compound
(Thupari et al., 2002; Takahashi et al.,
2004). While this cloud of uncertainty
lingered over the function of FAS in
energy homeostasis, the plot thick-
ened regarding an important role of250 Cell Metabolism 6, October 2007 ª2hypothalamic fatty acid metabolism
in energy homeostasis.
The direct infusion of oleic acids into
the third ventricle increases malonyl-
CoA in the hypothalamus and reduces
food intake (Obici et al., 2002, 2003).
The metabolism of fatty acids like oleic
acid leads to an increase in malonyl-
CoA by increasing cytoplasmic cit-
rate, which raises acetyl-CoA and
also allosterically activates acetyl-CoA
carboxylase (ACC). ACC converts
acetyl-CoA into malonyl-CoA (see
Figure 1). High malonyl-CoA levels
inhibit carnitine palmitoyltransferase 1
(CPT1), which catalyzes the rate-limit-
ing step of b-oxidation by translo-
cating fatty acids across the mito-
chondrial membrane (Figure 1). Thus,
during times of energy surplus,
increased malonyl-CoA levels both
serve as a substrate for FAS-induced
lipogenesis and at the same time007 Elsevier Inc.inhibit b-oxidation in the hypothala-
mus. The ‘‘malonyl-CoA hypothesis’’
was further supported by the demon-
stration that hypothalamic CPT1
inhibition (which is similar to the effect
of increased malonyl-CoA levels) re-
duces food intake and inhibits hepatic
glucose production (Obici et al., 2003).
Overexpression of malonyl-CoA de-
carboxylase (MCD, the enzyme that
degrades malonyl-CoA and thereby is
predicted to disinhibit CPT1) in the
mediobasal hypothalamus induces
food intake and increases hepatic
glucose production (He et al., 2006;
Hu et al., 2005). Thus, from these
studies it appears that malonyl-CoA
is indeed a key metabolic indicator in
the hypothalamus that serves as a
sensor of whole-body energy state.
Chakravarthy et al. (2007) now show
that the genetic inactivation of FAS in
the hypothalamus and pancreatic
b cells, achieved by mating rat insulin
promoter-Cre (RIP-Cre) transgenic
mice with floxed FAS KO mice, pro-
duces lean, hypophagic mice that
exhibit increased physical activity.
Importantly, this phenotype appears
to be entirely due to the hypothalamic
FAS deletion, as b cells were pheno-
typically and functionally normal in
these mice. Interestingly, this anorectic
phenotype also exhibits decreased
anxiety-like behavior. This is a promis-
ing finding in light of the propensity of
other centrally active anorectic agents,
such as the cannabinoid receptor 1 an-
tagonist rimonabant, to induce anxiety.
As predicted by the malonyl-CoA
hypothesis, hypothalamic FAS inacti-
vation led to an increase in malonyl-
CoA levels, and this might be the
main mechanism by which hypotha-
lamic FAS deletion leads to hypopha-
gia. However, the authors invoke an
additional mechanism. As a prior study
by the same authors showed that
hepatic PPARa activation requires he-
patic FAS activity, they speculate that
hypothalamic FAS regulates feeding
through PPARa. PPARa activation in
the brain has been shown to induce
lipogenic gene expression, and the
intracerebroventricular administration
of the PPARa activator WY14643 has
been shown to reduce glucose turn-
over in the whole body and especially
in adipose tissue (Knauf et al., 2006).
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PPARa activation by WY14643 in-
duces food intake in FAS/RIP-Cre mice
and restores the impaired expression
of lipogenic genes including CPT1 and
MCD while having no effect on food
intake in wild-type mice. Is malonyl-
CoA the primary signal that regulates
the hypothalamic control of food in-
take, or is malonyl-CoA’s main function
to serve as a substrate that FAS uses to
synthesize fatty acids that then acti-
vate PPARa? While the demonstration
that hypothalamic PPARa signaling is
able to bypass the anorectic effect of
hypothalamic FAS deletion is intriguing
and novel, it is not a formal proof that
FAS deletion regulates food intake via
PPARa signaling. It should also be
noted that the usage of the RIP-Cre
promoter for hypothalamic FAS dele-
tion does not lead to FAS deletion in
all hypothalamic neurons. Thus, it can-
not be ruled out that the effects of
PPARa activation in the FAS/RIP-Cre
phenotype result from PPARa signal-
ing in the ‘‘non-RIP-Cre’’ neurons that
retain normal FAS expression.
Whole-body PPARa knockout mice
have increased body weight due to in-
creased fat depots (Knauf et al., 2006).
This is in contrast to the hypothesis of
Chakravarthy et al. (2007) but could be
explained by PPARa effects in tissues
other than the brain. However, the hy-
pothalamic neuropeptide expression
profile of the PPARa knockout miceis opposite to that of the FAS/RIP-
Cre mice, arguing against PPARa as
the main mediator of the FAS deletion.
Likewise, it is not clear that the lack of
lipogenic gene expression in the FAS/
RIP-Cre mice is due to decreased
transcriptional activity of PPARa, de-
spite the fact that PPARa signaling
can normalize CPT1 and MCD expres-
sion in these mice.
In sum, the work by Chakravarthy
et al. (2007) provides definitive evi-
dence by genetic means that FAS
plays an important role in the regula-
tion of food intake and physical activ-
ity. In addition, the work demonstrates
that the hypothalamic cells that use
FAS as an integrator are neurons (as
opposed to glial cells). Whether the
phenotype of the FAS/RIP-Cre mice is
caused by a lack of PPARa activation
and is not simply a consequence of
the increased hypothalamic malonyl-
CoA levels awaits more stringent evi-
dence by complementary approaches.
It will be interesting to dissect the
PPARa-dependent from the PPARa-
independent effects of hypothalamic
FAS. A better mechanistic understand-
ing of how FAS deletion in the hypo-
thalamus induces a lean phenotype will
also have great relevance for antiobe-
sity drug development. Although many
questions remain regarding the inte-
gration of nutrient sensing into the cen-
tral control of energy homeostasis and
food intake, the study by ChakravarthyCell Metabolismet al. indicates that combating obesity
by targeting central fatty acid metabo-
lismseems tobea promising approach.
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